ArticleJournal of thoracic disease2024

Phase I/II study to evaluate consolidative hypofractionated radiation therapy for boosting the residual primary disease in combination with durvalumab after definitive chemoradiation therapy for stage III non-small cell lung cancer (NSCLC): study protocol for a prospective trial.

Brendan Coutu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.